Results 201 to 210 of about 13,010 (282)

Human IDO2 exhibits unique binding affinities distinct to those of human IDO1

The FEBS Journal, EarlyView.
Although indoleamine 2,3‐dioxygenase 2 (IDO2) is highly homologous to IDO1, it displays markedly lower catalytic activity. We found that IDO2 binds L‐tryptophan (L‐Trp) in a flipped orientation stabilized by the IDO2‐specific residue His143. Replacement of His143 with the IDO1‐equivalent tyrosine restored an IDO1‐like binding mode and increased ...
Shunsuke Nogi, Ayumu Takahashi, So Murakami, Nami Adachi, Tina Fujimoto, Yohta Fukuda, Taku Yamashita, Tsuyoshi Inoue, Hirofumi Tsujino   +8 more
wiley   +1 more source

Suicidality risk of cancer caregivers: a systematic review and meta-analysis of observational studies. [PDF]

Ann Med
Zhu XY, Hu LY, Jin MY, Tung TH.
europepmc   +1 more source

AHR activation by uraemic solutes [PDF]

Nature Reviews Nephrology, 2019
openaire   +2 more sources

Suppression of Indoleamine 2,3‐Dioxygenase Enhances Immune Responses to the Therapeutic Vaccine for Chronic Hepatitis B

Hepatology Research, EarlyView.
Indoleamine 2,3‐dioxygenase (IDO) activity modulates immune responses to the therapeutic HBV vaccine NASVAC. Genetic or pharmacological suppression of IDO enhanced vaccine efficacy in mice, and lower serum kynurenine levels predicted favorable responses in humans, suggesting IDO as both a therapeutic target and a biomarker.
Yohei Shirakami, Soranobu Ninomiya, Takayasu Ideta, Ayumu Kanbe, Toshihide Maeda, Daisuke Minowa, Daisuke Taguchi, Masaya Kubota, Hiroyasu Sakai, Kenji Imai, Yasuko Yamamoto, Hiroyasu Ito, Kuniaki Saito, Osamu Yoshida, Yoichi Hiasa, Masahito Shimizu   +15 more
wiley   +1 more source

Pancreatic Cystic Neoplasm Risk Among Individuals With Diabetes. [PDF]

JAMA Netw Open
Cho IR, Chang SH, Lee SH, Han KD, Chung KH, Lee MW, Choi JH, Paik WH, Ryu JK.   +8 more
europepmc   +1 more source

Effectiveness and safety of two‐drug regimens containing an integrase inhibitor and reverse transcriptase inhibitor in a cohort of virologically suppressed people with HIV: Data from the COMBINE‐2 study

HIV Medicine, EarlyView.
Abstract Objectives This study assessed real‐world effectiveness and safety of switching to dual therapy regimens consisting of an integrase inhibitor (INSTI), and reverse transcriptase inhibitor (RTI), among suppressed people living with HIV in Europe.
Cristina Mussini, Cassidy Henegar, Lambert Assoumou, Stephane de Wit, Margaret Johnson, Eugenia Quiros‐Roldan, Chris Kenyon, Colin Deschanvres, David Zucman, Frank Post, Roya Movahedi, Laura Comi, Julie Fox, Geoffrey Liegeon, Charlotte Martin, Jonathan Edwards, Giorgio Tiecco, Marc Delforge, Leigh Ragone, Bryn Jones, Jean van Wyk, Michael Aboud, Carl Fletcher, Anton Pozniak, Vani Vannappagari   +24 more
wiley   +1 more source

Accelerated neurostimulation protocols for auditory hallucinations: a systematic review and meta-analysis. [PDF]

Front Psychiatry
Hotz T, Kosyakova N, Sharma M.
europepmc   +1 more source

Are Phenotypic Baseline Characteristics Related to Abolition of AHR After Benralizumab and Dupilumab?

Clinical &Experimental Allergy, EarlyView.
Philipp Suter, Robert Greig, Rory Chan, Brian J. Lipworth   +3 more
wiley   +1 more source

Risk of end‐stage renal disease in Korean patients with type 2 diabetes according to cumulative low‐density lipoprotein cholesterol levels

Journal of Diabetes Investigation, EarlyView.
High cumulative LDL‐C levels increase ESRD risk in type 2 diabetes, particularly among patients using insulin, those receiving multiple antidiabetic medications, and those with longer diabetes duration. Longer exposure to elevated LDL‐C further increases risk, underscoring the need for intensive LDL‐C control.
Da‐Yeon Lee, Kyung‐Do Han, Ji‐Hee Ko, Han‐Na Jang, Sun Joon Moon, Hye‐Mi Kwon, Se‐Eun Park, Won‐Young Lee, Eun‐Jung Rhee   +8 more
wiley   +1 more source

Bellmunt Risk Score as a Prognostic Tool in Metastatic Castration-Resistant Prostate Cancer Survival.

JAMA Netw Open
Büttner T, Klümper N, Ellinger J, Ritter M, Krausewitz P.   +4 more
europepmc   +1 more source